Keith T. Flaherty

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance

  Nature Communications · 2026-06-24

• Figure S8 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S9 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S6 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S1 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S2 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S7 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S10 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S4 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S5 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Figure S11 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

  2026-06-17

• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I

  JCO Precision Oncology · 2026-06-01

• Editor’s Note: Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation

  Cancer Research · 2026-03-16

• Abstract A024: DeepVul: A multi-task transformer model for joint prediction of gene essentiality and drug response

  Cancer Research · 2025-12-04

• Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01